At a glance
ClinicalIndex Comparison RecordN/ACompleted· 201 enrolled
Drug / intervention
bevacizumab [Avastin]drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Non-interventional, Post-authorization Study to Observe in Daily Clinical Practice the Treatment Duration of Patients Treated With Avastin (Bevacizumab) in 1st Line mCRC in Belgium
In Brief
An observational study evaluating bevacizumab [Avastin] for Colorectal Cancer. Completed, enrolled 201 participants across 19 sites.
Detailed Summary
This observational study will assess the treatment duration, progression-free survival, reason for stopping treatment and patient and tumor characteristics of bevacizumab \[Avastin\] treatment in patients with metastatic colorectal cancer. Data will be collected for approximately 34 months. The target sample size is \>300 patients.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer
CountriesBelgium
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2010
First PostedMar 2010
Primary CompletionJun 2013
TodayJul 2026
First PostedMar 18, 2010
Enrollment StartJan 1, 2010
Primary CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 16.3 years ago
Interventions
bevacizumab [Avastin]drug
As prescribed by physician